We will now resume the meeting.
For this hour, we are continuing the study of the Patented Medicine Prices Review Board's guidelines.
Returning to us are Dr. Mitchell Levine, chairperson, and Mr. Douglas Clark, executive director.
I'm assuming, gentlemen, that you gave your statement last week. Do you have another statement this week?